Close

Jump to:

  • Navigation
  • Content
  • Footer
Kurk hero image

Kurk

Follow

A delicious, daily alternative to pharmaceuticals in the management of inflammation-related illnesses.

119%
 - 
Funded 9 Mar 2023
£350,004 target
£419,002 from 195 investors
More
Less

Business overview

Location London, United Kingdom
Social media
Website kurk.life/
Sectors Food & Beverage Mixed Digital/Non-Digital Mixed B2B/B2C
Company number 12680542
Incorporation date 18 Jun 2020
More
Less

Investment summary

Type Equity
Valuation (pre-money) £7.1M
Equity offered 5.57%
Share price £4.75
Tax relief

EIS

More
Less

Business highlights

  • £3.3m+ DTC sales in UK/EU/Australia*
  • Fully integrated Biotech, trademarked formulations and IP
  • Proven DTC model with 53% repeat rate
  • Over 33,000 happy customers in 4 countries
More
Less

Key features

  • Secondary Market
  • Seedrs nominee min. £14.25 +
  • Direct investment min. £10,000.00 +
  • Idea
  • Investor Perks
  • Key Information
  • Team
  • Updates
  • Investors 195
  • Discussion
  • Documents

Idea

Introduction

Pain-killer overuse is a common problem in the developed world, and many inflammatory issues are mistreated. Kurk is a delicious, daily alternative to pharmaceuticals in the management of inflammation-related illnesses (for example, arthritis, inflammatory bowel conditions, skin disorders including acne, cardiovascular disease). Kurk is 100% a natural product made from plants with zero synthetics and our mission is to help millions of people manage common health issues, naturally.

Having each fought and won their own battles with cancer, Dr. Harrison Weisinger and Trent Scanlen together embarked on a personal and professional journey to optimise their health naturally. After studying curcumin - a plant compound in the turmeric plant, the opportunity was clear. Curcumin has breathtaking anti-inflammatory and anti-cancer properties, but is poorly absorbed due to its crystallised form. Research into Curcumin has been booming - rarely is this seen and is an indicator of worldwide interest in this plant compound.

After 4 years of extensive scientific, medical and customer research, across multiple iterations of product development and testing, Kurk was created - our 100% plant-based curcumin drink, designed for maximum taste and absorption.

Using our trademarked MyCelle+™ formulation and manufacturing technology, produced in our own purpose-built lab in Twickenham, we can improve the absorption of difficult plant compounds.

Backed by Tom Hardy, Tinie Tempah and renowned investor Lyndon Lea, we are now looking to increase our investor base and execute on our plan. Our Customers love us and we are proud to have made a real difference in their lives, offering them a natural alternative to standard painkillers.

Substantial accomplishments to date

After 5 years we have built 3 brands and a Bioscience company and own all of our own supply chain and IP. Our team of seasoned entrepreneurs have extensive experience in this industry and all of our focus is on scaling Kurk. Our shareholders receive shares in our holding company that owns the brands and bioscience company.

Working within a disciplined resource allocation we have achieved:

1. We have impressed 33,000+ customers generating £3.3m+* in online sales in UK/EU and Australia. We have had exceptional customer feedback generating 4.5 stars on Trustpilot with over 2000+ reviews.

2. Created a clean processing technique MyCelle+ ™ that has produced a natural curcumin micellar emulsion, MyCurc+™ (without synthetics) and a plant based preservative Phytoarmour ™ with B2B and licensing potential.

3. Launched our new brand Kurk with 3 flavours (online only) with an incredible 53% repeat purchase rate after only 8 months of trading.

4. Established our biotech laboratory in Twickenham to develop and enhance our products and conduct scientific trials for optimised human health.

5. Developed numerous formats (Micellar liquid, gel and powder) using our trademarked micellar curcumin. In the future, this is planned for inclusion into beauty products, pet products, children's vitamins and B2B food and nutraceutical collaborations.

Our Food Scientist Hannah explains why Kurk is different:

* based on unaudited management accounts.

Monetisation strategy

Kurk is a D2C subscription business with thousands of customers using our products as part of their daily health routine. After years of continual testing, we believe we have developed the optimal product to scale - the crucial combination of a high repeat purchase rate, and IP. We now plan to roll out our proven product into retail and new markets.

We have export opportunities worldwide, and an abundance of interest within the scientific, medical and food industry and have ambitious plans to scale.

We are well positioned across three growing markets:

Having funded this company with Founder + Friend's funds, we believe we have the discipline to operate carefully while at the same time achieving maximal gains. We also have an exciting pipeline of products that are now ready for launch worldwide through retail, online and B2B licensing channels.

Use of proceeds

1. Growth (40%) - Execute on our retail rollout plans and drive volume in existing DTC channels.

2. Licensing/ Export (20%) - Supply agreements for human and pet health markets, through existing partnerships in the UK, US, China, EU, UAE and Australia.

3. Product (20%) - We will expand existing range and move pipeline products into production, retail and licensing.

4. R&D (20%) - Evaluate, through medico-scientific collaborations in UK and abroad, the benefits of Kurk in the management of inflammatory conditions, including arthritis, Alzheimer's prevention and gut health.

Investor Perks

Please note that any discounts, rewards and/or offers listed by a company in its campaign are subject to the terms and conditions applied by that company. It is the company’s responsibility to honour such discounts, rewards and/or offers and Seedrs does not take any responsibility for them.

Key Information

Debt

The company has the following outstanding loans:

1. £304,516 Founder loans with no interest rate attached. The loan is to be repaid on exit.
2. £151,078 HSBC Bounceback Loan at an interest rate of 2% per annum. The loan is to be repaid May 2030.

The funds raised from this investment round will not be used to repay these loans.

Open an account to get access to the team members of Kurk

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This webpage has been approved as a financial promotion by Seedrs Limited ("Seedrs"), which is authorised and regulated by the Financial Conduct Authority. It is not intended to be a promotion of any individual investment opportunity and is not an offer to the public. The summary information provided about investment opportunities on this webpage is intended solely to demonstrate the types of investments available on the Seedrs platform, and any investment decision should be made on the basis of the full campaign. Full campaigns are available to investors who have become authorised to invest on the Seedrs platform. All investment activities take place within the United Kingdom, and any person resident outside the United Kingdom should ensure that they are not subject to any local regulations before investing.

Seedrs does not make investment recommendations to you. No communications from Seedrs, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Seedrs does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Seedrs, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £7,103,592

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

Pitch type

There are 5 types of investment pitch available on Seedrs.

  • Equity
  • Convertible
  • Fund
  • Cohort
  • Secondary

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Seedrs nominee

This shows if you are able to choose, when making an investment, that you be represented by, and your shareholding be managed by, the Seedrs nominee.

Find out more

Custodian

If you invest in this Campaign, Seedrs will act as Custodian rather than provide our standard nominee service. This is due to the fact that the business is not directly involved in the share sale and Seedrs will not benefit from any rights under a shareholder agreement. As a result, Seedrs will handle administrative tasks as we do normally, but you will not have information or voting rights, updates from the business, preemption on future fundraising, or ongoing support about business trading activity.

Learn more about Custodian here

Secondary market

This shows if the business has opted-in or opted-out of allowing its shares to be bought and sold on the secondary market.

Find out more

Direct investment

This is an option to invest and hold shares 'directly' in the company (rather than via the Seedrs Nominee). This option is only available to those investing over the threshold amount, which is determined by the fundraising company.

If you choose to hold your shares directly, you will be responsible for any contractual or administrative arrangements with the company you are investing in.

Find out more

Payment options

We are not able to accept card payments for investments into this sector. You can pay for your investment by creating a bank transfer, using funds in your investment account or create a Pay by Bank payment. Your investment will only be completed once the funds have reached our account.

Business Involvement

This Campaign offers shares for sale in business that is not directly involved in this Campaign or the sale. As a result, the Campaign and post-investment experience, including investor rights, will differ from a business-led campaign on Seedrs. Most notably, the business will not engage with investors in the discussion forums both during and after the sale or provide any updates to investors.

Learn more here

Payment options

We are not able to accept Pay by Bank payments for investments into this sector. You can pay for your investment with a card payment, by creating a bank transfer or by using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Drawdowns

This campaign offers the ability to pay for an investment by drawdowns.

Warning

You are following a link outside of www.seedrs.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel